The Hancock® Valved Conduit for Right Ventricular Outflow Tract Reconstruction in Sheep for Assessing New Devices.

Q3 Medicine Journal of Heart Valve Disease Pub Date : 2017-07-01
John P Carney, Lindsey M Zhang, Jeffrey J Larson, Matthew T Lahti, Nicholas A Robinson, Agustin P Dalmasso, Richard W Bianco
{"title":"The Hancock® Valved Conduit for Right Ventricular Outflow Tract Reconstruction in Sheep for Assessing New Devices.","authors":"John P Carney,&nbsp;Lindsey M Zhang,&nbsp;Jeffrey J Larson,&nbsp;Matthew T Lahti,&nbsp;Nicholas A Robinson,&nbsp;Agustin P Dalmasso,&nbsp;Richard W Bianco","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim of the study: </strong>Xenograft conduits have been used successfully to repair congenital heart defects, but are prone to failure over time. Hence, in order to improve patient outcomes, better xenografts are being developed. When evaluating a conduit's performance and safety it must first be compared against a clinically available control in a large animal model. The study aim was to evaluate a clinically available xenograft conduit used in right ventricular outflow tract (RVOT) reconstruction in a sheep model.</p><p><strong>Methods: </strong>RVOT reconstruction was performed in 13 adult and juvenile sheep, using the Medtronic Hancock® Bioprosthetic Valved Conduit (Hancock conduit). The method had previously been used on patients, and a newly modified variant termed 'RVOT Extraction' was employed to facilitate the surgical procedure. Animals were monitored over predetermined terms of 70 to 140 days. Serial transthoracic echocardiography, intracardiac pressure measurements and angiography were performed. On study completion the animals were euthanized and necropsies performed.</p><p><strong>Results: </strong>Two animals died prior to their designated study term due to severe valvular stenosis and distal conduit narrowing, respectively. Thus, 11 animals survived the study term, with few or no complications. Generally, maximal and mean transvalvular pressure gradients across the implanted conduits were increased throughout the postoperative course. Among 11 full-term animals, seven conduits were patent with mild or no pseudointimal proliferation and with flexible leaflets maintaining the hemodynamic integrity of the valve.</p><p><strong>Conclusions: </strong>RVOT reconstruction using the Hancock conduit was shown to be successful in sheep, with durable and efficient performances. With its extensive clinical use in patients, and ability for long-term use in sheep (as described in the present study) it can be concluded that the Hancock conduit is an excellent control device for the evaluation of new xenografts in future preclinical studies.</p>","PeriodicalId":50184,"journal":{"name":"Journal of Heart Valve Disease","volume":"26 4","pages":"472-480"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Heart Valve Disease","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim of the study: Xenograft conduits have been used successfully to repair congenital heart defects, but are prone to failure over time. Hence, in order to improve patient outcomes, better xenografts are being developed. When evaluating a conduit's performance and safety it must first be compared against a clinically available control in a large animal model. The study aim was to evaluate a clinically available xenograft conduit used in right ventricular outflow tract (RVOT) reconstruction in a sheep model.

Methods: RVOT reconstruction was performed in 13 adult and juvenile sheep, using the Medtronic Hancock® Bioprosthetic Valved Conduit (Hancock conduit). The method had previously been used on patients, and a newly modified variant termed 'RVOT Extraction' was employed to facilitate the surgical procedure. Animals were monitored over predetermined terms of 70 to 140 days. Serial transthoracic echocardiography, intracardiac pressure measurements and angiography were performed. On study completion the animals were euthanized and necropsies performed.

Results: Two animals died prior to their designated study term due to severe valvular stenosis and distal conduit narrowing, respectively. Thus, 11 animals survived the study term, with few or no complications. Generally, maximal and mean transvalvular pressure gradients across the implanted conduits were increased throughout the postoperative course. Among 11 full-term animals, seven conduits were patent with mild or no pseudointimal proliferation and with flexible leaflets maintaining the hemodynamic integrity of the valve.

Conclusions: RVOT reconstruction using the Hancock conduit was shown to be successful in sheep, with durable and efficient performances. With its extensive clinical use in patients, and ability for long-term use in sheep (as described in the present study) it can be concluded that the Hancock conduit is an excellent control device for the evaluation of new xenografts in future preclinical studies.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
汉考克®瓣膜导管在绵羊右心室流出道重建中的应用
研究背景和目的:异种移植物导管已成功用于修复先天性心脏缺陷,但随着时间的推移,容易失效。因此,为了改善患者的预后,正在开发更好的异种移植物。在评估导管的性能和安全性时,必须首先将其与临床可用的大型动物模型对照进行比较。本研究的目的是评估临床可用的异种移植导管在绵羊右心室流出道(RVOT)重建中的应用。方法:采用美敦力Hancock®生物假体有瓣导管(Hancock导管)对13只成年羊和幼年羊进行RVOT重建。该方法以前曾用于患者,并采用了一种称为“RVOT提取”的新改良变体来促进手术过程。在70到140天的预定期限内对动物进行监测。进行了一系列经胸超声心动图、心内压测量和血管造影。研究完成后,对动物实施安乐死并进行尸检。结果:两只动物分别因严重瓣膜狭窄和远端导管狭窄而在指定的研究期限前死亡。因此,11只动物在研究期间存活下来,很少或没有并发症。一般来说,在整个术后过程中,植入导管的最大和平均跨瓣压力梯度增加。在11只足月动物中,7只导管通畅,轻度或无假内膜增生,具有柔韧的小叶,保持了瓣膜的血流动力学完整性。结论:采用汉考克导管重建绵羊RVOT是成功的,具有持久和高效的性能。由于汉考克导管在患者中的广泛临床应用,以及在绵羊中长期使用的能力(如本研究所述),可以得出结论,汉考克导管是未来临床前研究中评估新型异种移植物的优秀对照装置。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Heart Valve Disease
Journal of Heart Valve Disease 医学-心血管系统
CiteScore
1.00
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
期刊介绍: The Journal of Heart Valve Disease (ISSN 0966-8519) is the official journal of The Society for Heart Valve Disease. It is indexed/abstracted by Index Medicus, Medline, Medlar, PubMed, Science Citation Index, Scisearch, Research Alert, Biomedical Products, Current Contents/Clinical Medicine. It is issued bi-monthly in one indexed volume by ICR Publishers Ltd., Crispin House, 12A South Approach, Moor Park, Northwood HA6 2ET, United Kingdom. This paper meets the requirements of ANSI standard Z39.48-1992 (Permanence of Paper).
期刊最新文献
ABO Blood Group: A Risk Factor for a Cardiovascular Disease in Adults in Morocco Anti-Hypertensive Medication in Geriatric Population with HFpEF Comparison of Clinical Characteristics and Outcomes in Patients with STEMI in Croatia and Kosovo Radiofrequency Ablation of Ventricular Arrhythmias on Bioprosthetic Valve, a Never Found Case Before An Interesting Case of Heart Failure in a Patient with Bicuspid Aortic Valve - Unveiling the Diagnosis of Amyloidosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1